Ignite Creation Date:
2024-05-06 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03535441
Status:
COMPLETED
Last Update Posted:
2018-05-24
First Post:
2018-05-11
Brief Title:
HMGB1 Release From Hemorrhagic Shock Patients
Sponsor:
Xingui Dai
Organization:
First Peoples Hospital of Chenzhou
Study Overview
Official Title:
Evidence for SIRT1 Mediated HMGB1 Release From Kidney Cells in the Early Stages of Hemorrhagic Shock
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is reported that high mobility group box 1 HMGB1 a non-histone nuclear protein can serve as an alarmin with damage associated molecular patterns to activate immune responses in the early stages of hemorrhagic shock HS However the origin of HMGB1 and how it is released following HS is poorly understood In this study we teased out this mechanism We try to record the concentration of serum HMGB1 protein following HS in clinical patients
Detailed Description:
The study was approved by the First Peoples Hospital of Chenzhou Hunan PR China Consent was obtained from patients in their hospital course Eighteen patients were enrolled for each group In addition Acute Physiological and Chronic Health Evaluation II APACHE II score was used to evaluate the severity and morbidity of HS patients Serial blood samples were collected at indicated time points on hospital admission for HS patients 0 2 4 8 24 and 72 h following HS Levels of HMGB1 were detected by ELISA according to the kit manufacturers instructions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None